Forum Πρωτοβάθμιας Φροντίδας Υγείας
ΠΦΥ -Εκπαίδευση => Συζητήσεις πάνω σε ιατρικά θέματα => Μήνυμα ξεκίνησε από: Argirios Argiriou στις 31 Οκτωβρίου 2013, 17:28:58
-
Το ανέβασε ήδη ο Διακομιστής σε άλλο σημείο του φόρουμ αλλά νομίζω ότι αξίζει να σταθεί και από μόνο του ως μια ξεχωριστή δημοσίευση:
31/10/2013.
του Καρδιολόγου Χρήστου Ντέλλου,
Διευθυντή του Καρδιολογικού Τμήματος του Τζάνειου Νοσοκομείου.
Διδάκτωρα του Πανεπιστημίου Αθηνών.
Xarelto και ξερό ψωμί; Νέα αντιπηκτικά σε καιρούς οικονομικής μαρμαρυγής.
http://ntellos.gr/index.php/arthra/kolpikh-marmarygh-antipiktika/xarelto-kai-ksero-psomi
-
Αργύρη έχει δίκιο ο @Medicus. Δεν τη γλυτώνεις από τις φαρμακευτικές...
-
Xarelto Fails Phase III Trial.
Bayer and Johnson & Johnson’s Janssen Research & Development have acknowledged that their Xarelto® (rivaroxaban) has failed a Phase III trial assessing the blockbuster anticoagulant in patients with a recent embolic stroke of undetermined source (ESUS).
The companies said the Phase III NAVIGATE ESUS missed its primary efficacy endpoint of superiority over aspirin in reducing the risk of stroke (ischemic, hemorrhagic, and undefined stroke; transient ischemic attack with positive neuroimaging) and systemic embolism.
NAVIGATE ESUS was halted early at the recommendation of the study’s Independent Data Monitoring Committee, after a planned interim analysis showed comparable efficacy between patients treated with Xarelto and those treated with aspirin for secondary prevention of stroke and systemic embolism.
The study’s primary safety endpoint was major bleeding according to the criteria of the International Society on Thrombosis and Haemostasis. Bleeding rates were “very low overall and within the expected range,” Janssen said, though both companies acknowledged that increased bleeding was observed in the rivaroxaban arm compared to the low-dose aspirin arm.
https://www.genengnews.com/gen-news-highlights/xarelto-fails-phase-iii-trial-in-esus/81255021 (https://www.genengnews.com/gen-news-highlights/xarelto-fails-phase-iii-trial-in-esus/81255021)
-
Rivaroxaban vs. Warfarin for High-Risk Antiphospholipid Antibody Syndrome
David Green, MD, PhD reviewing Pengo V et al. Blood 2018 Jul 12
The trial was terminated early due to an excess of adverse events, including arterial thrombosis and major bleeding, with rivaroxaban.
https://www.jwatch.org/na47161/2018/07/19/rivaroxaban-vs-warfarin-high-risk-antiphospholipid?query=etoc_jwgenmed&jwd=000100032085&jspc=GP (https://www.jwatch.org/na47161/2018/07/19/rivaroxaban-vs-warfarin-high-risk-antiphospholipid?query=etoc_jwgenmed&jwd=000100032085&jspc=GP)